Barclays Maintains Boston Scientific at Equal-Weight, Cuts Target to $45

Barclays maintained its Equal-Weight rating on Boston Scientific and lowered its price target to $45 from $48. The revised target implies 5.4% upside from the Oct. 29 close of $42.69.